Gegenanzeigen · Capecitabine Teva
Capecitabine Teva 150 mg film-coated tablets Capecitabine Teva 500 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 7
HOS-215392 · Präparat HOS-155434
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or fluorouracil, • History of severe and unexpected reactions to fluoropyrimidine therapy, • Known complete dihydropyrimidine dehydrogenase (DPD) deficiency (see section 4.4), • During pregnancy and lactation, • In patients with severe leukopenia, neutropenia, or thrombocytopenia, • In patients with severe hepatic impairment, • In patients with severe renal impairment (creatinine clearance below 30 mL/min), • Recent or concomitant treatment with brivudine (see section 4.4 and 4.5 for drug-drug interaction), • If contraindications exist to any of the medicinal products in the combination regimen, that medicinal product should not be used.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): brivudine (HOS-091415) creatinine (HOS-086273) fluorouracil (HOS-086023)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T15:40:00Z · SHA-256 360b33238effee7033c9ecfa3731a36e172b67d4837e971f09a6e80d5cda73df · Passage 92235f7924ae07177b1cfbbde5f3feb07b3a47431098f206c54e6bb0d08115a2 · Zeichen 0–792 im Abschnitt